Telavancin Adds Option for Obese Patients with SSSIs
Publish date: October 18, 2011
FROM THE ANNUAL INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Dr. Slover is an employee of Astellas Pharma Global Development. The trials were supported jointly by Astellas Pharma Global Development and Theravance.
